SYRE (Spyre Therapeutics) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRE Spyre Therapeutics Inc SYRE
26 GF Score
Price $90.25
! 3 Warning Signs
View Full Analysis

What is Spyre Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Spyre Therapeutics  (NAS:SYRE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Spyre Therapeutics Cyclically Adjusted PB Ratio Related Terms


Spyre Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Cyclically Adjusted PB Ratio Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.47 0.46 0.56

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.30 0.56 0.82 1.54

SYRE vs TGTX, IMVT, IBRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Cyclically Adjusted PB Ratio falls into.


SYRE
26GF Score
Spyre Therapeutics Inc SYRE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Spyre Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Spyre Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=10.841/333.9520*333.9520
=10.841

Current CPI (Jun. 2026) = 333.9520.

Spyre Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 126.943 241.428 175.592
201612 117.204 241.432 162.118
201703 106.270 243.801 145.566
201706 95.130 244.955 129.693
201709 84.242 246.819 113.981
201712 75.490 246.524 102.262
201803 65.320 249.554 87.411
201806 83.812 251.989 111.073
201809 72.043 252.439 95.306
201812 69.830 251.233 92.822
201903 100.815 254.202 132.443
201906 86.327 256.143 112.551
201909 68.971 256.759 89.707
201912 51.644 256.974 67.114
202003 36.714 258.115 47.501
202006 85.347 257.797 110.559
202009 76.229 260.280 97.806
202012 72.891 260.474 93.453
202103 63.115 264.877 79.574
202106 60.694 271.696 74.601
202109 51.759 274.310 63.013
202112 42.519 278.802 50.930
202203 31.190 287.504 36.229
202206 34.393 296.311 38.762
202209 27.456 296.808 30.892
202212 19.244 296.797 21.653
202303 12.865 301.836 14.234
202306 -64.001 305.109 -70.051
202309 -60.613 307.789 -65.765
202312 -0.025 306.746 -0.027
202403 -0.892 312.332 -0.954
202406 4.304 314.175 4.575
202409 3.338 315.301 3.535
202412 6.007 315.605 6.356
202503 5.422 319.799 5.662
202506 7.504 322.561 7.769
202509 7.481 324.800 7.692
202512 7.155 324.054 7.374
202603 6.532 330.213 6.606
202606 10.841 333.952 10.841

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Spyre Therapeutics Business Description

Other Exchanges 3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score

Get the complete analysis for SYRE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.25
Price